Search

Displaying results 9651 - 9660 of 10000 in total
  1. Drug

    KF-0210

    go.drugbank.com/drugs/DB17476
    Investigational

    KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.

  2. Drug

    BI-836880

    go.drugbank.com/drugs/DB17484
    Investigational

    BI-836880 is a humanized bispecific nanobody that targets VEGF and Ang2.

  3. Drug

    CPGJ602

    go.drugbank.com/drugs/DB17485
    Investigational

    CPGJ602 is a recombinant anti-EGFR human-mouse chimeric monoclonal antibody.

  4. Drug

    DSP107

    go.drugbank.com/drugs/DB17501
    Investigational

    DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.

  5. Drug

    M-701

    go.drugbank.com/drugs/DB17504
    Experimental

    M-701 is a recombinant anti-EpCAM/CD3 bispecific antibody.

  6. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting … VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers.

  7. Drug

    RO7296682

    go.drugbank.com/drugs/DB17531
    Investigational

    RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells. … RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

  8. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  9. Drug

    IO-202

    go.drugbank.com/drugs/DB17548
    Investigational

    IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.

  10. Drug

    Alrizomadlin

    go.drugbank.com/drugs/DB17549
    Investigational

    Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.[A257281,A257286]